Molecular neonatal screening for homocystinuria in the Qatari population.
We report the results of molecular neonatal screening for homocystinuria (cystathionine beta-synthase deficiency) in neonates of Qatari origin, developed in conjunction with a novel biochemical screening approach. DNA was extracted from dried blood spots (DBS); the prevalent Qatari CBS gene mutation p.R336C (c.1006C>T) and a second mutation were tested with specific TaqMan assays. Over a period of 2 years we screened 12,603 neonates and identified six affected neonates homozygous for p.R336C. There were 225 heterozygous carriers for p.R336C. One additional child with homocystinuria detected through biochemical screening was homozygous for a mutation not previously identified in Qatar. Homocystinuria in the Qatari population has an incidence of 1:1,800, the highest in the world and even higher than previously estimated. Allele frequency of the mutation p.R336C is approximately 1%, displaying a significant deviation from Hardy Weinberg equilibrium. In conclusion, first-line molecular neonatal screening is technically feasible and may be developed as an option for presymptomatic identification of genetic disorders caused by specific mutations or a limited number of prevalent mutations. However, sensitivity for the diagnosis of disorders caused by various mutations is limited even in a homogeneous population such as Qatar.
Institute of Human Genetics, Ruprecht-Karls-University, Heidelberg, Germany. humgen@i-med.ac.at
Johannes
J
Zschocke
Moustafa
M
Kebbewar
Hongying
H
Gan-Schreier
Christine
C
Fischer
Junmin
J
Fang-Hoffmann
Julia
J
Wilrich
Ghassan
G
Abdoh
Tawfeg
T
Ben-Omran
Noora
N
Shahbek
Martin
M
Lindner
Hilal
H
Al Rifai
Abdul Latif
AL
Al Khal
Georg F
GF
Hoffmann
D044466:Asian People / Q000235:genetics*; D004252:DNA Mutational Analysis; D005260:Female; D006579:Heterozygote; D006712:Homocystinuria / Q000175:diagnosis* / Q000235:genetics*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D015997:Neonatal Screening; D011780:Qatar